"We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies ...

SPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising ...

Invivyd (IVVD) announced that the SPEAR Study Group has issued their consensus recommendation for a clinical study design to evaluate the effects ...